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The TLR/IL-1R pathway is a critical signaling module that is misregulated in pathologies
like inflammation and cancer. Extracts from turmeric (Curcuma longa L.) enriched
in curcumin and carbonyls like turmerones have been shown to exert potent anti-
inflammatory effects. The present study evaluated the anti-inflammatory activity,
cytotoxic effect and the underlying mechanism of a novel chemically modified, non-
carbonyl compound enriched Curcuma longa L. (C. longa) extract (CMCE). CMCE (1 or
10 µg/mL; 14 h) significantly decreased LPS (50−100 ng/mL) induced TNF-α and IL-1β
production in THP-1 cells, human, and mouse whole blood as measured by ELISA. LPS-
induced IRAK1, MAPK activation, TLR4 expression, TLR4-MyD88 interaction, and IκBα
degradation were significantly reduced in CMCE pre-treated THP-1 cells as assessed
by Western blotting. CMCE (30, 100, and 300 mg/kg; 10 days p.o.) pre-treated and
LPS (10 mg/kg) challenged Swiss mice exhibited attenuated plasma TNF-α, IL-1β,
nitrite, aortic iNOS expression, and vascular dysfunction. In a PI permeability assay,
cell lines derived from acute myeloid leukemia were most sensitive to the cytotoxic
effects of CMCE. Analysis of Sub-G1 phase, Annexin V-PI positivity, loss of mitochondrial
membrane potential, increased caspase-3, and PARP-1 activation confirmed CMCE
induced apoptosis in HL-60 cells. IRAK inhibition also sensitized HL-60 cells to CMCE
induced cytotoxicity. The present study defines the mechanism underlying the action of
CMCE and suggests a therapeutic potential for its use in sepsis and leukemia.
Keywords: caspase-3, chemically modified Curcuma longa extract, endotoxemia, interleukin-1 receptor-
associated kinase 1, mitochondrial membrane potential
Abbreviations: AML, Acute myeloid leukemia; DOX, Doxorubicin; IRAK1, Interleukin-1 receptor-associated kinase 1; LPS,
Lipopolysaccharide; MAPKs, Mitogen-activated protein kinases; SRB, Sulforhodamine B; TGA, Thioglycollate; TLRs, Toll-
like receptors.
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INTRODUCTION
Chronic inflammation is associated with allergy, atherosclerosis,
cancer, arthritis, and autoimmune disorders (Medzhitov, 2008).
TLRs are well-known for their role in mediating signaling
through pathogen-associated molecular patterns (PAMPs) of
microbial products (Mogensen, 2009). Activation of TLR4 by
LPS has been implicated in the pathophysiology of endotoxemic
septic shock and lethality (Porter et al., 2010). LPS binding
to TLR4 receptor induces MyD88 recruitment and subsequent
activation of IRAK4. IRAK4 dependent IRAK1 and TNF
receptor-associated factor 6 (TRAF6) activation induces NFκB
transcription in an IκB kinase (IKK) dependent manner (Janssens
and Beyaert, 2003). At the same time, IRAK1 can also induce the
activation of the MAPK pathway (Janssens and Beyaert, 2003).
NF-κB signaling and the MAPK-AP-1 axis often contribute to
the secretion of cytokines and generation of an inflammatory
response (Janssens and Beyaert, 2003; Palsson-McDermott and
O’Neill, 2004).
Association of inflammation with development and
progression of cancer depends on direct or indirect effects
of cytokines, chemokines, growth factors, and receptors on
tumor cells or their microenvironment (Balkwill and Mantovani,
2001; Kornblau et al., 2010). The aberrant regulation of cytokines
and growth factors has also been observed in leukemias such
as AML (Van Etten, 2007), suggesting the importance of
inflammatory cytokine and chemokine antagonists in the
prevention and treatment of malignant diseases (Balkwill
and Mantovani, 2001). A recent study by Greten et al. (2004)
demonstrated the role of NFκB in colitis-associated cancer using
conditional inactivation of IKKβ in colonic epithelial cells. This
resulted in a remarkable decrease in the tumor incidence (Greten
et al., 2004). Overexpression and activation of IRAK1 and IRAK4
have been demonstrated in several types of cancer (Rhyasen and
Starczynowski, 2015). Specifically, a role for IRAK in myeloid
leukemia as well as in the progression of breast cancer has been
shown recently (Rhyasen and Starczynowski, 2015; Wee et al.,
2015). Epidemiological data suggests an inverse relationship
between the occurrence of certain cancers and anti-inflammatory
therapy (Rayburn et al., 2009).
Turmeric (Curcuma longa L.) has been traditionally used as
an ayurvedic medicine and in the preparation of food (Prasad
and Aggarwal, 2011). The bioactive components of C. longa
are curcuminoids such as curcumin, demethoxycurcumin,
bis-demethoxycurcumin and several volatile oils like d-
α-phellandrene, d-sabinene, cinol, borneol, zingiberene,
and sesquiterpenes (Prasad and Aggarwal, 2011). The oil
derived from C. longa contains several carbonyl and non-
carbonyl components like ar-turmerone, β-turmerone,
α-turmerone, sesquiphellandrene, zingiberene, curcumene,
curlone, germecrone, curzerene, curcumenol, iso-curcumenol,
β-bisabolene, curdione, neocurdione, germacrene D, gamma-
elemene, furanodieneone, furanodiene with trace amounts of
curcumin, demethoxy curcumin, and bisdemethoxy curcumin
(Ray et al., 2006). Previous reports have highlighted the anti-
inflammatory effects of fractions enriched in curcumin and
tumerones (Sandur et al., 2007; Bagad et al., 2013). However,
the activity profile of the non-carbonyl components is not
known.
Therefore, the present study was undertaken to investigate the
potential anti-inflammatory and cytotoxic properties of a novel,
chemically modified C. longa extract enriched in non-carbonyl
components and to delineate the mechanism of action of this
extract.
MATERIALS AND METHODS
Materials
RevertAidTM H Minus first strand cDNA synthesis kit
was obtained from Fermentas Life Sciences (Vilnius,
Lithuania). 2X Maxima SYBR Green RT-PCR Master Mix
was purchased from Roche Applied Science (Lewes, UK). FBS
and Penicillin/Streptomycin were obtained from Invitrogen
(Carlsbad, CA, USA). Dexamethasone was purchased from EMD
Millipore (Billerica, MA, USA). Antibodies against p-p38, p38,
p-ERK1/2, ERK1/2, p-JNK1/2, JNK1/2, MyD88, Caspase-3, and
IκBα were purchased from Cell Signaling Technology (Danvers,
MA, USA). Anti-TLR4, anti-pIRAK1, anti-total IRAK1 and
anti-cleaved PARP-1 were obtained from Santacruz Biotech Inc.
(Santa Cruz, CA, USA). LPS (from E. coli 0111:B4), brewer TGA
medium, 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazol
carbocyanine iodide (JC-1), propidium iodide (PI), SRB, DOX
and all other chemicals used in the present study were purchased
from Sigma Chemicals, Co. (St. Louis, Mo, USA).
Instrumentation
FTIR, NMR, and Mass were taken on a Perkin-Elmer Spectrum
RX1 Spectrophotometer (4000−450 cm−1); (Waltham, MA,
USA), Bruker Avance 400 (400 MHz FT-NMR with, 5 mm multi-
nuclear inverse probe head, low and high-temperature facility
and HRMAS accessory; USA) and Micromass Quattro II (USA),
respectively.
Preparation of CMCE Extract
A hexane soluble fraction of C. longa was prepared as described
earlier (Rana et al., 2015). The hexane soluble fraction of
C. longa (5 g) was mixed with semicarbazide hydrochloride
(10 g) and ethyl alcohol (100 ml, 99% pure) with a few
drops of glacial acetic acid, and then refluxed for 48 h.
Further addition of semicarbazide hydrochloride (10 g) at
an interval of 5 to 6 h was continued until the total
amount of semicarbazide hydrochloride came up to 50 g.
The completion of the reaction was monitored by TLC and
finally by HPLC for the confirmation of complete removal
of the carbonyl portion. The reaction mixture was cooled,
filtered, the residual portion was washed with ethyl alcohol
and the filtrate was concentrated under vacuum. Further HPLC
grade hexane was added to the concentrate and refluxed for
5 h for the extraction of Curcuma longa L. extract (CMCE)
from ethanol. It was filtered again and concentrated under
vacuum. No crystal formation was observed on retaining the
CMCE.
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Cell Culture and Treatments
THP-1 cells (Human monocytic leukemia), HL-60 cells (Human
Caucasian promyelocytic leukemia), MCF-7, and MDA-MB-
231 (Human Caucasian breast adenocarcinoma) were obtained
from American Type Culture Collection (Rockville, MD, USA).
THP-1 and HL-60 cells were cultured in RPMI-1640 medium
while MCF-7 and MDA-MB-231 cells were grown in DMEM
containing 10% heat-inactivated FBS, 100 IU/mL penicillin,
and 100 µg/mL streptomycin. THP-1 cells were pre-treated
with CMCE (1 or 10 µg/mL) or dexamethasone (standard
anti-inflammatory drug; 1 µg/mL) for 14 h followed by LPS
(100 ng/mL) stimulation for 1.5 h. Experiments related to human
blood were carried out after receiving proper ethics approval
from the Institute, King George’s Medical University (KGMC)
human research ethics committee. Human blood was collected
from the antecubital vein in heparin tubes (Vacutainer) at
the department of transfusion medicine, KGMC after receiving
prior permission from healthy volunteers. Peripheral blood
mononuclear cells (PBMCs) were isolated using percoll density
gradient centrifugation as described previously (Repnik et al.,
2003; Tiwari et al., 2011). All ethical procedures were in
accordance with the Declaration of Helsinki. For cytotoxicity
assays, HL-60, MCF-7, and MDA-MB-231 cells and human
PBMCs were treated with CMCE (1−100 µg/mL) or commercial
anti-tumor standard drug DOX (1 µg/mL) for 20 h. CMCE or
standard drugs were dissolved in DMSO (0.1% (v/v) vehicle) for
cell culture experiments. The vehicle control had no effect on
cytotoxicity (data not shown).
Whole Blood Culture
Blood from anesthetized male Swiss albino mouse was collected
by cardiac puncture in 2.5% trisodium citrate under aseptic
conditions in accordance with the institutional guidelines under
an approved ethical protocol. Human and mouse whole blood
was diluted 1:10 in RPMI-1640 and treated with CMCE (1 and
10 µg/mL) or dexamethasone (1 µg/mL) for 14 h followed by LPS
(50 ng/mL) treatment for 8 h. TNF-α and IL-1β in the culture
supernatants were measured using ELISA (Thurm and Halsey,
2005).
Cell Viability
PI Permeability
THP-1, HL-60, MCF-7, MDA-MB-231 cells, and human PBMCs
(1 × 106 cells/mL) treated with CMCE were incubated with PI
(5 µg/mL in PBS) for 5 min at room temperature, and then
a minimum of 10,000 events were acquired by flow cytometry
and subsequently analyzed using the CellQuest program (FACS
Calibur; Becton-Dickinson, San Jose, CA, USA; Kumar et al.,
2010a).
SRB Assay
Cell viability was determined using the SRB method as described
previously (Skehan et al., 1990). Briefly, HL-60 cells were fixed
with 80% TCA (w/v) for 1 h at 4◦C. The fixed cells were
washed five times with tap water, air-dried and stained with
SRB solution 0.4% (w/v) in 1% acetic acid for 30 min at
room temperature. After incubation, excess SRB was removed
by washing four times with 1% acetic acid and air dried.
10 mM Tris-base (pH 10.5) was added to each well to
solubilize SRB by shaking the plate for 5 min on a shaker,
and the absorbance of SRB was measured at 564 nm by
ELISA plate reader (BioTek Instrument Inc., Winooski, VT,
USA).
Cytokine Measurement
The levels of cytokines (TNF-α and IL-1β) were measured using
conventional ELISA kits (BD OptEIATM set; BD Biosciences, San
Diego, CA, USA) according to the manufacturer’s instructions
(Tiwari et al., 2011).
Nitrite Measurement
Total nitrite content in the plasma and cell culture supernatant
was measured by the Griess reagent. To estimate nitrite content
in plasma and supernatant, cadmium pellets (Sigma, St. Louis,
MO, USA) were added to reduce nitrate to nitrite. An equal
volume of Griess reagent was added to the respective samples
and incubated for 30 min at 37◦C. Nitrite concentration
was estimated by measuring the absorbance at 545 nm
and 630 nm (wavelength correction) against sodium nitrite
as standard using ELISA plate reader (Biotek Instrument
Inc., Winooski, VT, USA). Total nitrite was reported as
percent (%) nitrite release (Kumar et al., 2010b; Rana et al.,
2015).
Western Blotting and
Co-immunoprecipitation
Whole cell extracts from THP-1 and HL-60 cells after various
treatments were prepared in lysis buffer (0.01 M Tris-HCl
(pH 7.4), 0.1 M NaCl, 0.001 M EDTA (pH 7.4), aprotinin
(1 µg/mL), phenylmethylsulfonyl fluoride (100 µg/mL),
pepstatin (20 µg/mL), sodium orthovanadate (Na2VO4,
2 mM), sodium fluoride (2 mM) and 1% Triton X-100).
THP-1 or HL-60 cell lysates were centrifuged at 13,000 × g
for 10 min and protein concentrations were measured by
using BCA reagent. For co-immunoprecipitation, Sepharose
A beads (20 µL) were conjugated with anti-TLR4 (1 µg)
using a pre-adsorption buffer (50 mM HEPES; pH 7.4,
150 mM NaCl, and 1% Triton X-100) for 3 h at 4◦C on
rotating platform followed by a single wash with cold PBS.
Protein (500 µg) was added to TLR4 conjugated beads
and incubated overnight at 4◦C. Subsequently, protein or
immunoprecipitates were separated on 8−10% SDS-PAGE
and transferred to PVDF membrane. After blocking with
5% BSA in TBST, the membranes were probed with primary
antibody against various proteins of interest. The specific
bands were detected by enhanced chemiluminescence (Tiwari
et al., 2011). Western blots results were expressed as fold
change in relative image quant units in comparison to control.
Protein phosphorylation was normalized against their respective
total protein expression and loading control. Densitometry
quantification of the immunoprecipitation blots was normalized
after considering the total input expression of the respective
protein.
Frontiers in Pharmacology | www.frontiersin.org 3 July 2016 | Volume 7 | Article 223
fphar-07-00223 July 25, 2016 Time: 16:11 # 4
Rana et al. Turmeric Regulates Inflammation and Cytotoxicity
LPS-Induced Endotoxemia Mouse Model
Male Swiss albino mice (20−25 g; 8 weeks old) obtained
from the National Laboratory Animal Centre at the CSIR-
Central Drug Research Institute were used in this study as per
Institutional Animal Ethics Committee guidelines. In the present
study, male mice were used since they were readily available
at the animal house facility and this also helped in avoiding
interference of the female hormones, if any, on the studied
parameters. All animal procedures were followed in accordance
with Institutional Animal Ethics Committee, which follows the
guidelines of the Committee for the Purpose of Control and
Supervision of Experiments on Animals and conforms to the
Indian National Science Academy international norms. After
acclimatization, mice were randomly grouped into six groups
of six animals each; Control (vehicle; group I), LPS (10 mg/kg;
group II), CMCE (30, 100, and 300 mg/kg; group III, IV
and V, respectively) and dexamethasone (10 mg/kg; group VI).
CMCE was administered via oral gavage in 0.25% carboxymethyl
cellulose sodium suspension (CMC; vehicle) for 10 days prior
to LPS (10 mg/kg; i.p.) challenge given for 12 h (Schmidt
et al., 2007). Dexamethasone was injected intraperitoneally
1 h before LPS (10 mg/kg; i.p.) challenge (Schmidt et al.,
2007). No mortality was observed after LPS administration.
The dose selected for LPS administration is on the lines of
reported dose where mortality was also not observed (Xu et al.,
2012).
TGA-Induced Peritonitis Mouse Model
Male Swiss albino mice (20−25 g; 8−10 weeks old) were
randomly distributed into six groups of four animals each; vehicle
control (0.25% CMC w/v; group I), TGA (4%; group II; i.p. 24
and 72 h), CMCE (30, 100, or 300 mg/kg; group III, IV, and V,
respectively; p.o. 10 days) and dexamethasone (1.5 mg/kg; group
VI; i.p. 1 h) (Montesinos et al., 2006). Peritoneal fluid containing
leukocytes was collected at 24 and 72 h after TGA injection by
flushing the peritoneal cavity with 5 mL of cold PBS. The number
of cells recruited into the peritoneal cavity was determined with a
Neubauer chamber (Rana et al., 2015).
RNA Isolation and Real-Time RT-PCR
Total RNA was extracted from mouse aortic tissue by TRIzol
reagent (Invitrogen, Carlsbad, CA, USA) and cDNA was
prepared using the RevertAidTM H Minus first strand cDNA
synthesis kit (Fermentas, Vilnius, Lithuania). Quantification of
mRNA by real-time PCR was carried out using the Light Cycler R©
480II Real-Time PCR system (Roche Applied Science, Lewes,
East Sussex, UK) along with 2X Maxima SYBR Green RT-
PCR Master Mix. The cDNA was amplified using the following
primers: forward 5′-TGCATGGACCAGTATAAGGCAAGC-3′
and reverse 5′-CTCCTGCCCACTGAGTTCGTC-3′ for iNOS;
and forward 5′-CGTTGACATCCGTAAAGACC-3′ and reverse
5′-TGGAGCCACCGATCCACACA-3′ for β-Actin. Samples were
incubated at 95◦C for 5 min, followed by 45 cycles, each
consisting of a 15 s denaturation at 95◦C, annealing at 59◦C
for 20 s, and extension at 72◦C for 15 s. Relative fold difference
between the groups was calculated by using the comparative cycle
threshold (2−11Ct) method. β-Actin was used as an internal
standard to calculate the relative expression (Rana et al., 2015).
Endothelial Function
Vasoreactivity was monitored in the thoracic aorta of LPS
and CMCE treated mice as described earlier (Singh et al.,
2011). Briefly, thoracic aorta was cut and mounted in organ
baths containing 10 mL Krebs bicarbonate solution. Changes
in isometric force were amplified via Compact Research System
Amplifiers and were recorded with force transducers (FSG-01;
Budapest, Hungary) using SPEL Solution Pack for Experimental
Laboratories ADVANCE ISOSYS data acquisition and analysis
software. After equilibration, the aortic rings were exposed
to KCl Krebs buffer (80 mM) to assess the maximum tissue
contractility. Cumulative concentration-dependent contraction
responses to phenylephrine (PE) (10−100 µM) were assessed.
The endothelium function was then assessed by monitoring
relaxation to acetylcholine (Ach) (300 pM−300 µM) in PE
(1 µM) pre-contracted rings. Finally, tissue contractility and
viability were assessed by exposing the rings to KCl Krebs buffer
(80 mM) in all groups (Singh et al., 2011).
Bioavailability Studies
Preparation of standard and quality control samples was done
(Supplementary Material). CMCE was administered orally at a
dose of 300 mg/kg in mice. Blood samples were collected at pre-
defined time intervals (5, 15, 30, 60, 120, 180, 240, 360, and
1440 min; n = 3). Plasma was harvested by centrifuging the
blood at 4500 × g for 10 min. To 0.2 mL of plasma, 0.5 mL
of methanol was added and thoroughly vortex mixed for 2 min.
After centrifugation at 3000× g for 10 min, the supernatant layer
was transferred into a clean test tube, concentrated to dryness
under vacuum, reconstituted in 50 µL of methanol, 20 µL of
which were injected into the HPLC system (Shimadzu, Kyoto,
Japan) for analysis (Jain et al., 2007).
Cell Cycle and Apoptosis
The DNA staining in HL-60 cells (1 × 106 cells/mL)
was performed using hypotonic PI solution (50 µg/mL PI
with 0.03% NP-40 in 0.1% sodium citrate) as described
earlier (Krishan, 1975). The cells undergoing apoptosis were
obtained from the sub-G1 region of the DNA distribution
histograms. Analysis of cellular apoptosis was assessed using
the Annexin V-FITC/PI kit (BD Biosciences, San Jose, CA,
USA). Stained cells were acquired by flow cytometer and
analyzed using CellQuest software (Becton Dickinson, San
Jose, CA, USA) in the case of apoptotic markers or by
Modfit software (Verity Software, Topsham, ME, USA) for
the cell cycle analysis. PARP-1 and caspase-3 activation were
monitored as markers of apoptosis in HL-60 cells by Western
blotting.
Mitochondrial Membrane Potential
HL-60 cells were stained with JC-1 (5 µM) in RPMI-1640 for
10 min as previously described (Kumar et al., 2010a). Cells
were subsequently washed twice with PBS, and the pellet was
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re-suspended in PBS for FACS analysis. A minimum of 10,000
events was acquired to assess JC-1 fluorescence in both FL-1
(monomers, green fluorescence) and FL-2 channels (aggregates,
red fluorescence) using FACS Calibur (Becton-Dickinson, San
Jose, CA, USA).
STATISTICAL ANALYSIS
Results are expressed as the mean ± standard error (S.E).
The statistical differences between groups were determined by
one-way ANOVA followed by Tukey’s or Dunnett’s post hoc
test, and p-value equal to or less than 0.05 was considered as
statistically significant. All statistical analysis were performed
with the GraphPad Prism 5.0 program (GraphPad Inc., La Jolla,
CA, USA).
RESULTS
CMCE Reduces Pro-Inflammatory
Cytokine Production in LPS-Treated
THP-1 Cells and Whole Blood from
Human and Mouse
A cell viability test was performed at 14 h in THP-1 cells to
exclude toxic doses of CMCE. CMCE reduced cell viability
by ∼73% at 30 µg/mL and ∼93% at 100 µg/mL doses as
measured by the PI permeability assay while no significant
cytotoxicity was observed at lower doses (1 and 10 µg/mL) as
compared control cells (Supplementary Figure S1). Therefore,
these lower doses of CMCE were further assessed in THP-1
cells as well as in human and mouse whole blood to determine
the effects on LPS-induced TNF-α and IL-1β production. Pre-
treatment with CMCE (1 and 10 µg/mL) for 14 h decreased
LPS-induced TNF-α (∼70 and 76%, respectively) and IL-1β (∼49
and 96%, respectively) production in THP-1 cells (Table 1).
This effect of CMCE was comparable to the effect of the
known anti-inflammatory agent, dexamethasone, which reduced
LPS-induced TNF-α and IL-1β (∼77 and 50%, respectively)
production in THP-1 cells (Table 1). To further these results,
we tested the effect of CMCE in whole blood derived from
mouse or human, a physiologically more relevant system. CMCE
pre-treatment (1 and 10 µg/mL) dose-dependently decreased
LPS-induced TNF-α production in human (∼17 and 46%,
respectively) and mouse (∼16 and 45%, respectively) whole
blood (Table 1). CMCE (1 and 10 µg/mL) also decreased
IL-1β production in human (∼17 and 57%, respectively) and
mouse (∼24 and 64%, respectively) whole blood (Table 1).
Dexamethasone showed a similar reduction in TNF-α and
IL-1β production in blood cells (∼59 and 67%, respectively)
(Table 1).
CMCE Inhibits Activation of IRAK1 and
MAPKs in LPS-Stimulated THP-1 Cells
Mitogen-activated protein kinases (p38, JNK, and ERK)
often operate downstream of the TLR-IRAK pathway and
TABLE 1 | Curcuma longa L. extraxt (CMCE) reduces LPS-induced
pro-inflammatory cytokines production in THP-1 cells, human and mouse
whole blood.
Groups TNF-α (ρg/mL) IL-1β (ρg/mL)
Control 11.6 ± 2.7 6.8 ± 2.1
LPS 3374 ± 357.5∗∗∗ 198.6 ± 39.9∗∗∗
THP-1 cells LPS+CMCE 1 µg/mL 1016 ± 150.6### 101.5 ± 2.1#
LPS+CMCE 10 µg/mL 826.1 ± 213.7### 8.7 ± 0.2###
LPS+Dexamethasone
1 µg/mL
762.9 ± 136.4### 99.4 ± 4.3#
Control 27.4 ± 3.7 14.1 ± 5.1
LPS 1691 ± 120.2∗∗∗ 1040 ± 60∗∗∗
Human whole
blood
LPS+CMCE 1 µg/mL 1397 ± 115.6 864.4 ± 43.4
LPS+CMCE 10 µg/mL 911 ± 54.6### 439.6 ± 56.5###
LPS+Dexamethasone
1 µg/mL
699.2 ± 67.9### 343.4 ± 45###
Control 109.1 ± 21.1 121.8 ± 16.4
LPS 431.8 ± 22∗∗∗ 416.5 ± 18.7∗∗∗
Mouse whole
blood
LPS+CMCE 1 µg/mL 361.3 ± 26 313.5 ± 44.1
LPS+CMCE 10 µg/mL 236 ± 11.3### 150 ± 31.5###
LPS+Dexamethasone
1 µg/mL
174.7 ± 21.5### 138.8 ± 32.5###
Data were expressed as the mean (at least n = 3) ± SEM; ∗∗∗p < 0.001 control
vs. LPS; #p < 0.05, ###p < 0.001 LPS vs. LPS+CMCE or LPS+dexamethasone.
are intimately involved in cytokine production (Huang et al.,
2004). Therefore, we examined phosphorylation of IRAK1
and MAPKs in LPS stimulated THP-1 cells. LPS-induced
IRAK1 phosphorylation in THP-1 cells (∼1.9 fold) was
significantly attenuated in CMCE (1 and 10 µg/mL; 14 h)
pre-treated cells (∼1.4 and 1.5 fold, respectively) (Figure 1A).
Further, LPS significantly augmented phosphorylation of
p38 (∼2.8 fold), JNK1/2 (∼1.5 fold) and ERK1/2 (∼1.8
fold) in THP-1 cells (Figures 1B–D). However, CMCE (1
and 10 µg/mL) pre-treated THP-1 cells showed marked
reduction in LPS-induced p38 (∼1.4 and 1.5 fold, respectively;
Figure 1B), JNK1/2 (∼1.3 and 1.4 fold, respectively, Figure 1C)
and ERK1/2 (∼1.5 and 1.8 fold, respectively; Figure 1D)
phosphorylation as compared to cells stimulated with LPS
alone.
CMCE Attenuates the LPS-Induced
TLR4-MyD88 Interaction, TLR4
Expression and IκBα Degradation in
THP-1 Cells
TLR4 triggers the downstream signaling pathway by recruiting
the MyD88 adaptor protein to its receptor (Medvedev et al.,
2002). Expression of TLR4 after LPS stimulation was monitored
in a time-dependent manner. As shown earlier (Muzio
et al., 1998; Medvedev et al., 2002), LPS-induced TLR4
expression was unchanged as compared to control cells at
early time points (5 min, 15 min); however it was significantly
augmented at later time points (1, 1.5, and 2 h) (data
not shown). In contrast, TLR4-MyD88 complex formation
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FIGURE 1 | The effect of Curcuma longa L. extract (CMCE) on LPS-induced IRAK1 and MAPKs activation. Phosphorylation and expression of (A) IRAK1,
(B) p38, (C) JNK, and (D) ERK MAPK in CMCE pre-treated (1 and 10 µg/mL for 14 h) and LPS stimulated (100 ng/mL for 1.5 h) THP-1 cells. β-Actin was used as
an internal loading control. Values represent the mean ± SEM; ∗∗p < 0.01, ∗∗∗p < 0.001 control vs. LPS; #p < 0.05, ##p < 0.01, ###p < 0.001 LPS vs. LPS and
CMCE pre-treated cells. The blots are representative one of three similar experiments.
was significantly induced (∼1.7 fold) after 5 min of LPS
stimulation of THP-1 cells (Figure 2A), which was significantly
attenuated following CMCE (1 and 10 µg/mL) pre-treatment
(∼1.3 and 1.4 fold, respectively) (Figure 2A). Interestingly,
expression of TLR4 and MyD88 was unaltered at this time
point (Figure 2A). Similarly, LPS-induced TLR4 expression,
which was significantly augmented (∼1.6 fold) at later time
point (1.5 h) (Figure 2B), was also decreased in CMCE
(1 and 10 µg/mL) pre-treated THP-1 (∼1.4 and 1.6 fold,
respectively) cells (Figure 2B). We next examined the effect
of CMCE on LPS-induced IκBα degradation in THP-1 cells.
LPS-induced IκBα degradation (∼0.4 fold) was recovered
in CMCE (1 and 10 µg/mL) pre-treated THP-1 cells in
a dose-dependent manner (∼1.8 and 2.3 fold, respectively)
(Figure 2C).
CMCE Prevents LPS-Induced Adverse
Effects in Mice
Plasma levels of TNF-α, IL-1β, and total nitrite were significantly
(p < 0.001) increased in mice 12 h following LPS challenge
(10 mg/kg; Figures 3A,B). However, mice that were orally
gavaged with CMCE (30, 100, 300 mg/kg) daily for 10 days
prior to LPS challenge showed a significant reduction in LPS-
induced TNF-α (∼61, 71 and 75%, respectively), IL-1β (∼66,
86, and 93%, respectively) and nitrite production (∼53, 83, and
87%, respectively) (Figures 3A,B). These levels were comparable
to that seen with a 10 mg/kg dosage of dexamethasone
administered intraperitoneally to animals 1 h prior to LPS
challenge. Dexamethasone (10 mg/kg) pre-treated mice also
showed an inhibition of plasma TNF-α, IL-1β and nitrite
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FIGURE 2 | The effects of CMCE on LPS-induced TLR4-MyD88 interaction, TLR4 expression, and IκBα degradation. (A) TLR4-MyD88 interaction in
THP-1 cells pre-treated with CMCE (1 and 10 µg/mL; 14 h) and stimulated with LPS (100 ng/mL; 5 min). Cell lysates were immunoprecipitated with anti-TLR4 and
immunoblotted with MyD88. Expression of (B) TLR4 and (C) IκBα in THP-1 cells pre-treated with CMCE (1 and 10 µg/mL; 14 h) and further challenged with LPS
(100 ng/mL; 1.5 h). β-Actin was used as an internal loading control. Values represent the mean ± SEM; ∗∗p < 0.01, ∗∗∗p < 0.001 control vs. LPS; #p < 0.05,
##p < 0.01 LPS vs. LPS and CMCE pre-treated cells. The blots are representative one of three similar experiments.
production (∼78, 87, and 88%, respectively) (Figures 3A,B).
Furthermore, increased aortic iNOS expression (∼27 fold) in
LPS-challenged mice (Figure 3C) was significantly attenuated
in CMCE (30, 100, and 300 mg/kg) pre-treated mice (∼3, 1.9,
and 1.4 fold, respectively) as compared to the control group
(Figure 3C). Mice pre-treated with dexamethasone (10 mg/kg)
also showed attenuated iNOS expression (∼1.1 fold) (Figure 3C).
Because of the role of iNOS in endothelial dysfunction is well-
characterized (Titheradge, 1999; Draisma et al., 2010), we sought
to determine whether CMCE may mitigate this response via
its attenuation of iNOS expression. A significant (p < 0.001)
reduction in acetylcholine-induced endothelial relaxation in PE
pre-contracted rings was observed in the aorta from the LPS
treated group when compared to the control group (Figure 3D).
However, no change was seen in PE-induced contractions.
CMCE (100 and 300 mg/kg) or dexamethasone pre-treatment
(10 mg/kg) of LPS-challenged mice, significantly (p < 0.01,
p < 0.001) restored acetylcholine-induced endothelial relaxation
(Figure 3D). However, no change was observed at a lower dose of
CMCE (30 mg/kg).
To determine the effect of CMCE on inflammatory cell
migration in vivo, we studied the recruitment of cells into the
peritoneal cavity elicited by TGA. In particular, we observed
the expected increase in leukocytes found in peritoneal lavage
(21 × 106 cells/ mL lavage fluid; p < 0.001 at 24 h
and 27 × 106 cells/ mL lavage fluid; p < 0.001 at 72 h,
respectively) after TGA injection (Figure 3E). As predicted,
CMCE (30,100 and 300 mg/kg) pre-treatment significantly
attenuated transmigration of these cells (9 × 106, 8 × 106, and
7× 106 cells/ mL lavage fluid; p< 0.001, respectively) at 24 h and
(9 × 106, 8 × 106, and 6 × 106 cells/ mL lavage fluid; p < 0.001,
respectively) at 72 h in the peritoneal cavity of TGA-challenged
mice. Similarly, dexamethasone-treated mice showed reduced
leukocyte influx into peritoneal cavity at 24 and 72 h (6 × 106
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FIGURE 3 | The effects of CMCE in mice. Plasma (A) TNF-α, IL-1β and (B) nitrite production, (C) aortic iNOS mRNA expression, and (D) endothelial dysfunction
in CMCE (30, 100, and 300 mg/kg; 10 days p.o.) pre-treated and LPS- challenged (10 mg/kg; 12 h) male Swiss mice. (E) Inflammatory cell migration in CMCE (30,
100, and 300 mg/kg; 10 days p.o.) or dexamethasone (1.5 mg/kg; 1 h i.p.) pre-treated and 4% TGA- challenged mice. Migration of leukocytes was counted after 24
and 72 h of TGA challenge using Neubauer chamber. (F) Plasma concentration time profile of Compound (I). Values represent the mean (n = 3−6) ± SEM;
∗∗∗p < 0.001 control vs. LPS or TGA; #p < 0.05, ##p < 0.01, ###p < 0.001, $$$p < 0.001, @p < 0.05, @@p < 0.01, @@@p < 0.001 LPS vs. LPS+CMCE or
dexamethasone pre-treated groups.
FIGURE 4 | Effects of CMCE on cell viability of HL-60, MCF-7, MDA-MB-231 cells, and PBMCs. The cells were treated with different concentrations of CMCE
(1, 10, 30, and 100 µg/mL) or DOX (1 µg/mL) for 20 h and cell viability was determined by (A) PI permeability in HL-60, MCF-7, MDA-MB-231 cells, and PBMCs
(B) SRB assay in HL-60 cells. Values represent the mean (at least n = 3) ± SEM; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 control vs. CMCE or DOX treated cells.
cells/mL lavage fluid; p < 0.001, respectively) as compared to the
TGA group (Figure 3E).
Bioavailability Studies
In our preparation, the yield of CMCE was 3 g (40%).
The constituents of CMCE included zingiberine, curcumene,
β-bisabolene, β-sesquiphellandrene, curzerene, and a cyclic
derivative of the carbonyl compound 7,7-dimethyl-5-(2-p-
tolylpropyl)-6,7-dihydro-1,3,4-oxadiazepin-2-amine, compound
(I). The latter was identified and characterized as the major
marker compound present in CMCE, using 1H, 13C NMR,
and IR spectral analysis and mass spectrometry (Supplementary
Figure S2). Pharmacokinetic parameters were determined based
on the presence of compound (I) in CMCE, which was not
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FIGURE 5 | Effect of CMCE on Sub-G1 apoptosis and phosphatidylserine externalization. (A) Histogram and (B) bar diagram represent sub-G1 fraction as
analyzed by flow cytometer using hypotonic PI and (C) flow cytometric dot plot, (D) bar diagram representing Annexin V-PI staining in HL-60 cells treated with CMCE
(10 and 30 µg/mL) or DOX (1 µg/mL) for 20 h. Values represent the mean ± SEM; ∗∗p < 0.01, ∗∗∗p < 0.001 control vs. CMCE or DOX; ∗∗p < 0.01 control Annexin
V+ PI− cells vs. DOX, #p < 0.05, ##p < 0.01 control Annexin V+ PI+ cells vs. CMCE or DOX, @p < 0.05, @@p < 0.01, @@@p < 0.001 control Annexin V− PI+ cells
vs. CMCE or DOX treated cells.
less than 25%. Its purity was ascertained by TLC and HPLC,
and it was found to be more than 99% pure. Therefore, the
concentration of marker compound (I) was utilized to assess
the bioavailability of CMCE using plasma extracted from mice
orally gavaged with CMCE. The HPLC chromatogram of blank
plasma and plasma spiked with CMCE in which the marker
compound (I) was eluted at about 4.6 min (Supplementary
Figure S3). The HPLC chromatogram of plasma after 15 min
of CMCE administration showed compound (I) (Supplementary
Figure S4). All subjects showed early absorption of marker
compound (I), which appeared to peak at 15 min with plasma
levels of (I) measuring 41.29 ± 1.07 µg/mL (Figure 3F). By
240 min, the plasma concentration of compound (I) was below
the detection limit, indicative of rapid absorption and elimination
of the marker compound. Overall systemic availability of
(I) was found to be 32.65 ± 3.32 h∗µg/mL (equivalent to
CMCE).
Comparison of Efficacy of CMCE in
HL-60, MCF-7, MDA-MB-231 Cells, and
PBMCs
Since altered IRAK signaling has been associated with the
development of myeloid leukemia and breast cancer and since
we demonstrate here that CMCE modulates IRAK signaling
in THP-1 AML cells, we hypothesized that CMCE might
show cytotoxic effects in AML- and breast cancer-derived
cell lines. To that end, HL-60, MCF-7, and MDA-MB-231
cells were treated with 1, 10, 30, or 100 µg/mL CMCE.
A concentration-dependent effect on cytotoxicity was noted.
However, the most robust anti-proliferative effect of CMCE
leading to a maximum number of PI-positive cells was
observed in HL-60 cells (Figure 4A). The order of CMCE
sensitivity as demonstrated in term of PI positivity was MDA-
MB-231 cells < MCF-7 cells < HL-60 cells. Mechanistic
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FIGURE 6 | Effect of CMCE on mitochondrial membrane potential, caspase-3 and PARP-1 activation and IRAK1/4 inhibition. (A) Representative dot plot
and (B) Bar diagram depicting % positive JC-1 monomers (green fluorescence) in HL-60 cells treated with CMCE (10 and 30 µg/mL) or DOX (1 µg/mL) for 20 h.
Changes in transmembrane potential were assessed by flow cytometry using FL-1 (green) and FL-2 (red) channels. CMCE induced cleavage of (C) pro-caspase-3
and (D) PARP-1 in HL-60 cells. Cells treated with CMCE (10 µg/mL) or DOX (1 µg/mL) for 20 h and expression levels of pro-caspase-3 and PARP-1 were detected
by Western blotting. β-Actin was used as an internal loading control. The blots are representative one of three similar experiments. (E) HL-60 cells were treated with
3 or 10 µM concentration of IRAK1/4 inhibitor with or without CMCE (10 µg/mL) for 20 h. Cell death was assessed by flow cytometry with Annexin V-PI staining.
Values represent mean (n = 3) ± SEM; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 control vs. CMCE, CMCE+ IRAK1/4 inhibitor, or DOX treated cells; #p < 0.05 CMCE
vs. CMCE+IRAK1/4 inhibitor treated cells.
studies were carried out in HL-60 cells since CMCE induced
significantly more apoptosis in this cell line when compared
to other solid tumor cells like MCF-7 and MDA-MB-231.
To determine whether CMCE selectively acted on cancer
cells, primary human PBMCs were used as healthy, non-
transformed controls. CMCE (10 µg/mL) induced cell death
(∼25%) in HL-60 cells after 20 h, while no significant
cytotoxicity was observed at this dose in normal PBMCs
(Figure 4A). Since the extent of cell death induced by CMCE
at a lower dose (10 µg/mL) was significantly less in healthy
PBMCs when compared to HL-60 cells, it can be speculated
that CMCE may produce additional beneficial effects by
targeting the cancer cells more effectively than the healthy
ones. However, at higher doses a significant increase in cell
death was observed in PBMCs (Figure 4A). As expected,
DOX, a therapeutic commonly used in the treatment of
hematological malignancies, reduced the cell viability to an
extent similar to that seen with the 30 µg/mL dosage of
CMCE (∼51% vs. 59%) in HL-60 cells using the PI assay.
This cytotoxicity was independently confirmed using an SRB
assay, which is currently employed in the NCI-60 cell line
screen assay (Skehan et al., 1990). A dose-dependent (1, 10,
30, and 100 µg/ml) inhibitory effect on cell proliferation was
observed (∼6, 48, 72, and 78%, respectively) in CMCE-treated
HL-60 cells. This was comparable to the 48% inhibition of
proliferation seen in HL-60 cells treated with 1 µg/mL of DOX
(Figure 4B).
CMCE Induces Formation of an
Apoptotic Sub-G1 Peak and
Phosphatidylserine Externalization in
HL-60 Cells
Since the lower dose (1 µg/mL) of CMCE was ineffective in
inducing cytotoxicity (Figures 4A,B), the other relevant doses
of 10 and 30 µg/mL were chosen for carrying out mechanistic
studies. In particular, cell cycle analysis revealed the presence of
a sub-G1 peak in the DNA histogram distribution, indicating
the accumulation of a late apoptotic population after CMCE
treatment (10 and 30 µg/mL; 20 h). The sub-diploid population
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increased in a concentration-dependent manner (∼25 and 50%,
respectively) in CMCE treated cells (Figures 5A,B). DOX
(1 µg/mL) also induced sub-G1 apoptosis (∼26%) in HL-60
cells (Figures 5A,B). CMCE induced apoptosis of HL-60 cells
was also confirmed by Annexin V-FITC/ PI staining. Annexin
V is a Ca2+ dependent phospholipid-binding protein having a
high affinity for apoptotic cells with exposed phosphatidylserine
and is typically used in conjunction with PI to distinguish early
from late apoptotic cells (Vermes et al., 1995). Healthy cells
were negative for both Annexin V and PI. Apoptotic cells were
Annexin V positive and PI negative. Late apoptotic and necrotic
cells were positive both for Annexin V and PI (Figures 5C,D).
CMCE treatment enhances the proportion of late apoptotic
(Annexin V-FITC and PI-positive) and necrotic (PI-positive)
cells at 10 µg/mL (∼8 and 12%, respectively) and 30 µg/mL (∼25
and 33%, respectively) concentrations (Figures 5C,D). DOX
also significantly induced early apoptotic (∼18%), late apoptotic
(∼15%) and necrotic (∼18%) cell populations (Figures 5C,D).
HL-60 cells treated with CMCE showed increased numbers
of Annexin V and PI-positive cells which indicative of late
apoptosis. No significant sub-G1 peak and Annexin V-FITC
and PI-positive cells were detected in vehicle-treated HL-60
cells.
CMCE Induced Apoptosis Involves Loss
of Mitochondrial Membrane Potential,
Caspase-1, and IRAK
The HL-60 cells were treated with CMCE (10 and 30 µg/mL)
or DOX (1 µg/mL) for 20 h and mitochondrial membrane
potential loss was assessed by monitoring change in JC-
1 fluorescence. CMCE induced apoptosis through the
intrinsic pathway as was revealed by loss of mitochondrial
membrane potential. A dose-dependent increase (∼52 and
93%, respectively) in JC-1 monomers (green fluorescence)
was observed, indicating loss of mitochondrial membrane
potential (Figures 6A,B). Similarly, DOX treatment also
produced increases in JC-1monomers (∼46%) (Figures 6A,B).
Since, caspases play a vital role in the initiation and execution
of apoptosis and caspase-3 is an executioner caspase which
cleaves its substrate PARP-1 (Nunez et al., 1998), expression of
caspase-3 and PARP-1 was assessed in CMCE (10 µg/mL;
20 h) treated HL-60 cells. CMCE (10 µg/mL) or DOX
(1 µg/mL) significantly induced procaspase-3 cleavage
(∼0.7 fold each) and PARP-1 cleavage (∼1.2 and 1.5 fold,
respectively) (Figures 6C,D). Therefore, disruption in the
mitochondrial membrane potential further activated the
procaspase-3 and PARP-1 cleavage via procaspase-9. The
effect of the IRAK1/4 inhibitor on CMCE induced cytotoxicity
was evaluated. Although the 3 and 10 µM concentrations
of IRAK1/4 inhibitor alone had no significant effect on cell
death similar concentrations of IRAK1/4 inhibitor (3 and
10 µM) potentiated (∼1.4 and 1.6 fold, respectively) CMCE
(10 µg/mL) induced cell death (Figure 6E). This result implies
that inhibition of IRAK1/4 sensitizes HL-60 cells to CMCE
induced cytotoxicity.
DISCUSSION
The present study demonstrates, for the first time, the
anti-inflammatory and cytotoxic activity of a novel non-
carbonyl compound enriched Curcuma longa extract (CMCE) in
various models of inflammation and cytotoxicity. The present
modifications done to the Curcuma longa extract resulted in
enrichment of non-carbonyl components and the compound I,
while turmerones and curcumin were present in a negligible
amount. The cytotoxic effect in the two AML cells lines and the
anti-inflammatory effect in LPS-induced inflammation observed
in THP-1 cells and in vivo demonstrates the therapeutic potential
of this extract.
Although a controlled inflammatory response protects the
host against invading pathogens, its dysregulation leads to several
diseases such as cancer, atherosclerosis, rheumatoid arthritis and
septic shock (Mogensen, 2009). By using THP-1 cells and a
more physiologically relevant system of whole blood culture
(Thurm and Halsey, 2005), the present study demonstrates that
CMCE attenuates LPS-induced TNF-α and IL-1β production.
Since the whole blood model closely imitates in vivo conditions,
our findings also suggest the potential for effectiveness of CMCE
in vivo.
LPS-induced TLR4 activation leads to the recruitment of
MyD88, followed by subsequent induction of downstream
signaling molecules like IRAK1, MAPKs, and NFκB (Medvedev
et al., 2002). Moreover, phosphorylation of MAPKs (p38,
JNK, and ERK) via various transcription factors regulates the
production of inflammatory cytokines (Guha and Mackman,
2001). LPS mediated IκBα phosphorylation leads to its
ubiquitination and degradation and facilitates translocation
of NFκB to the nucleus (Kawai and Akira, 2007). The findings of
the present study demonstrate that CMCE by reducing IRAK1,
p38, JNK, ERK phosphorylation, and IκBα degradation may
affect the activation of downstream transcription factors like
AP-1, Elk-1, and NFκB, respectively and therefore attenuate
inflammatory cytokines production in THP-1 cells. Thus, it
is plausible that both the MAPK and the NF-κB pathway are
key to the anti-inflammatory effect of CMCE. Inhibition of
TLR4-mediated signaling can be achieved by either disruption
of the TLR4-MyD88 complex or by downregulation of receptor
itself (Methe et al., 2005; Piao et al., 2013). Expression and
co-immunoprecipitation experiments revealed that both TLR4
expression and TLR4-MyD88 interaction were necessary for
the observed anti-inflammatory effect of CMCE. Since, LPS-
mediated activation of MAPKs and NFκB signaling encourages
the binding of NFκB and AP-1 transcription factors to the
promoter of the TLR4 gene and subsequently leads to its
transcriptional up-regulation and cytokine production (Yan,
2006), our findings suggest that CMCE, by preventing the TLR4-
MyD88 interaction and downregulating the TLR4 receptor
attenuates LPS-induced pro-inflammatory cytokines production.
To determine its therapeutic relevance, CMCE was tested in
an LPS-induced endotoxemia mouse model which closely mimics
sepsis. Since, an earlier study from our laboratory showed that
a hexane-soluble extract of C. longa had a lipid-lowering effect
without altering liver enzymes (for 30, 100, and 300 mg/kg doses)
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(Singh et al., 2013), we used similar low, medium and high doses
of CMCE to monitor activity against LPS-induced endotoxemia
in a mouse model. In agreement with our in vitro results, plasma
pro-inflammatory cytokines were significantly attenuated in the
LPS-induced endotoxemia mouse model. Circulating cytokines
released during septicemia promote blunted vascular responses
due to impairment in endothelial function (Titheradge, 1999;
Draisma et al., 2010). Endothelial dysfunction is caused by
decreased eNOS and increased iNOS expression in the vessel wall
(Titheradge, 1999; Draisma et al., 2010). Therefore, suppression
of LPS-induced aortic iNOS expression and plasma nitrite
production by CMCE could be partially responsible for the
improved vascular relaxation when compared to groups treated
with LPS alone.
TGA-induced peritonitis is characterized by distinct phases
in which neutrophil influx occurs at an earlier time point
(up to 24 h) followed by macrophage infiltration at later
time points (48−72 h)(Melnicoff et al., 1989). In CMCE
treated mice, the peritoneal lavage leukocytes were significantly
reduced at 24 and 72 h suggesting that CMCE is likely to
inhibit transmigration of both neutrophils and macrophages
during the initiation and progression of the inflammatory
response.
Given that molecular inhibition of the IRAK pathway by
CMCE induced an anti-inflammatory effect and higher doses
produced a cytotoxic effect in THP-1 cells, it was considered
worthwhile to investigate the consequence of IRAK pathway
inhibition by CMCE on cytotoxicity in cancer cell lines.
Previous studies indicate an association of myeloid leukemia
with hyperactivation of the IRAK pathway (Rhyasen and
Starczynowski, 2015). At the same time, a small molecule
possessing anti-inflammatory and anti-tumor effects was found
to inhibit IRAK1 (Joh et al., 2011; Rhyasen and Starczynowski,
2015). Several FDA-approved drugs demonstrated enhanced
cytotoxicity when combined with an IRAK1/4 inhibitor (Li
et al., 2015). IRAK1 is also reported to drive breast cancer
cell metastasis, and its inhibition overcomes paclitaxel-induced
resistance (Wee et al., 2015). Therefore, HL-60, MCF-7, and
MDA-MB-231 cell lines were used to test the effect of CMCE on
cytotoxicity. Also in previous studies, C. longa extracts containing
curcumin and turmerones had been tested for similar activities in
these cell lines (Aratanechemuge et al., 2002; Sandur et al., 2007;
Yue et al., 2010). These cell lines are also a part of the NCI-60, the
cell line panel recommended for anti-cancer screening (Ikediobi
et al., 2006).
Loss of mitochondrial potential and activation of the intrinsic
pathway by CMCE is important since activating the intrinsic,
or the mitochondrial pathway of apoptosis is one of the
therapeutic approaches in AML (Kadia et al., 2016). ABT-199
showed significant mitochondrial-dependent activity in leukemia
cell lines, primary murine xenografts, and primary samples of
patients with AML including AML stem and progenitor cells
(Pan et al., 2014; Kadia et al., 2016). Current and future AML
therapy may involve the development of agents that target
specific mutant driver enzymes or proteins and drugs like CPX-
351, SGN-CD33A, and ABT-199 whose mechanism of action
and efficacy may be independent of mutational complexity (Stein
and Tallman, 2016). One effective strategy could be to combine
drugs with the non-overlapping mechanism of actions with
targeted molecular therapy agents (Stein and Tallman, 2016). The
combination studies for ABT-199 are already underway (Kadia
et al., 2016). Therefore, it will be interesting to assess the effect of
CMCE on AML patient samples in combination with known and
molecular targeted agents.
Although inhibition of the IRAK pathway by CMCE induced
an anti-inflammatory effect, IRAK1/4 inhibition alone was not
sufficient to induce cell death in HL-60 cells. However, IRAK
inhibition potentiated the cytotoxic activity of CMCE in HL-
60 cells. This means that mere inhibition of the IRAK pathway
is not sufficient to induce cell death. Therefore, it can be
speculated that enhanced sensitivity to CMCE induced cell death
in the presence of IRAK1/4 inhibitor can be due to enhanced
cooperativity between the IRAK dependent and independent
signaling pathways activated by CMCE. At the same time,
effective inhibition of IRAK by the IRAK1/4 inhibitor may also
account for an efficient cytotoxic effect of CMCE at the tested
dose. Therefore, CMCE due to its potential to inhibit the IRAK
pathway may have the dual potential of sensitizing the cells to
cytotoxicity and also participate in the phenomenon directly.
Although inflammation is associated with the development of
several cancers like colitis-associated colorectal cancer (Kim and
Chang, 2014), it will be interesting and worthwhile to investigate
the effect of CMCE in a model of cancer where inflammation is a
major underlying mechanism.
CONCLUSION
Curcuma longa L. extract (CMCE) was found to exert anti-
inflammatory effects in vitro and in vivo. It also promoted
a cytotoxic effect in cancer cells. CMCE modulated the
TLR4-MyD88-IRAK-MAPK-NFκB pathway in THP-1 cells and
regulated inflammatory cytokine production. CMCE ameliorated
LPS-induced adverse effects in mice. In HL-60 cells, the cytotoxic
effect was mediated by the intrinsic pathway of apoptosis,
leading to caspase-3 activation, which was further enhanced by
IRAK inhibition. Thus, CMCE sensitized the cells to cytotoxicity
and also participated in the phenomenon directly. Therefore,
molecular inhibition of the IRAK pathway by CMCE regulated
inflammation and cytotoxicity. For these reasons, CMCE may
have beneficial therapeutic applications in inflammatory and
proliferative disorders.
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